Alector (ALEC) said Thursday it has completed enrollment for PROGRESS-AD, a 76-week phase 2 trial assessing the safety and effectiveness of AL101/GSK4527226 in slowing early-stage Alzheimer's disease progression.
Alector and GSK (GSK) are co-developing AL101, an investigational monoclonal antibody targeting the sortilin receptor to increase brain progranulin levels, currently being evaluated in PROGRESS-AD, a global, randomized, double-blind, placebo-controlled phase 2 trial led by GSK.
The trial is evaluating two dose levels of AL101, with participants randomized to receive either the drug or a placebo intravenously, and its primary endpoint is disease progression measured by the Clinical Dementia Rating Sum of Boxes, a validated tool for assessing cognitive decline, the biotechnology company said.
Shares of Alector were down 1.9% in recent Thursday trading, while GSK's were up 1%.
Price: 0.96, Change: -0.02, Percent Change: -1.87
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。